<DOC>
	<DOCNO>NCT00645866</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epirubicin , docetaxel , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study side effect give epirubicin together docetaxel capecitabine see well work treat woman stage IIIA stage IIIB breast cancer .</brief_summary>
	<brief_title>Epirubicin , Docetaxel , Capecitabine Treating Women With Stage IIIA Stage IIIB Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Describe pathologic response rate chemotherapy-naive woman locally advance breast cancer ( stage IIIA IIIB ) 6 course sequential neoadjuvant therapy epirubicin hydrochloride combination docetaxel capecitabine . - Describe adverse event sequential epirubicin hydrochloride combination docetaxel capecitabine patient population . Secondary - Identify transcriptional profile differential expression candidate gene product confer chemosensitivity epirubicin hydrochloride , docetaxel , capecitabine . - Correlate differential expression know genetic polymorphism intracellular regulator involve metabolism epirubicin hydrochloride , docetaxel , capecitabine adverse event tumor response . - Assess individual patient variation clinical ( toxicity and/or activity ) , pharmacologic ( pharmacokinetic/pharmacodynamic parameter ) , and/or biologic ( correlative laboratory study result ) responses epirubicin hydrochloride , docetaxel , capecitabine due genetic difference proteins involved drug response ( transport , metabolism and/or mechanism action ) . OUTLINE : Patients receive epirubicin hydrochloride IV day 1 . Treatment repeat every 2 week 3 course . Beginning 2 week last dose epirubicin hydrochloride , patient receive docetaxel IV 1 hour day 1 oral capecitabine twice daily day 1-14 . Treatment docetaxel capecitabine repeat every 3 week 3 course . Patients undergo surgery . Blood sample collect baseline pharmacogenetic study . Tumor tissue sample collect baseline periodically treatment correlative laboratory study . After completion study treatment , patient follow every 3 month disease progression every 6 month 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer Stage IIIA IIIB disease ( T3 N1 M0 , T4 N1 M0 , T N2/N3 M0 ) Bidimensionally measurable evaluable disease Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 02 Platelet count ≥ 100,000 cells/μL Total bilirubin normal Hemoglobin ≥ 8.0 g/dL ANC ≥ 1,000 cells/μL AST ALT ≤ 2.5 time upper limit normal Creatinine clearance ≥ 50 mL/min serum creatinine normal Life expectancy ≥ 3 month No uncontrolled infection No chronic debilitate disease No lack physical integrity upper gastrointestinal tract Able swallow tablet No malabsorption syndrome No clinically significant cardiac disease well control medication ( e.g. , congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia [ New York Heart Association class IIIIV heart disease ] myocardial infarction within last 12 month ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer adequately treat noninvasive carcinoma No peripheral neuropathy ≥ grade 1 PRIOR CONCURRENT THERAPY : More 4 week since prior major surgery recover No prior chemotherapy regimen include adjuvant therapy No organ allograft No concurrent sorivudine bruvidine No concurrent cytostatic , cytotoxic , immunomodulating agent , radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>